– UK, London – Frontier IP (LON: FIPP), a specialist in commercializing intellectual property, today announced the appointment of Nigel Grierson and Dr. David Holbrook to its Board as Independent Non-Executive Directors with effect from 15 March 2023.
Dr. David Holbrook and Nigel Grierson will join the audit and remuneration committees on appointment and David will become Chair of the audit committee.
“I am delighted to welcome Nigel and David to our Board of Directors. Their extensive experience in technologies across sectors such as semiconductors and life sciences, and in working with early-stage technology companies will prove invaluable to the Group as commercialize and scale up our portfolio companies,” said CEO, Neil Crabb.
The company also announced the appointment of the current Independent Director, Professor Dame Julia King, Baroness Brown of Cambridge, as Senior Independent Director effective from 15 March 2023, and that Dr. Campbell Wilson will step down from the Board during April 2023.
The Company also announced that Dr. Campbell Wilson will step down from the Board in April 2022.
About Nigel Grierson
Nigel Grierson has 20 years of operating experience in the IT industry with positions in product development, marketing, and senior management, and, as Managing Director of venture capital funds managing investments of over $500 million in 70 technology start-up companies across Europe. Nigel’s early career was in product development; designing semiconductors for the telecom industry, process control systems for the automotive industry, and navigation/telemetry systems for the offshore oil exploration industry.
Nigel was a co-Managing Director of the Doughty Hanson Technology Fund, established in 2000, which was part of Doughty Hanson Private Equity Partners. Between 1984 and 2000, he held senior roles at Intel Corporation becoming Co-Director of EMEA for Intel Capital Group, and developing and leading a team to establish Intel as a leading corporate technology investor. Nigel ran strategic programs working directly for Intel’s then CEO Dr. Andrew Grove and COO Dr. Craig Barrett. Nigel is FCA qualified to run controlled functions and is an alumnus of the INSEAD Fontainbleau Advanced Management Program.
About Dr. David Holbrook
Dr. David Holbrook is a leading healthcare technology investment professional with 30years’of experience in the life sciences sectors. He has sat on more than 20 boards of directors during his career. David is currently a non-executive director at AIM quoted Oxford BioDynamics plc, where he also chairs the audit committee. He is also a senior advisor to digital health investor RYSE Asset Management and Chairman of The Liver Group Charity based at The Royal Free Hospital. David was also previously a General Partner/Venture Partner for MTI Ventures LLP. David has a 40-year history in the healthcare space, firstly as a physician and then in senior business development roles with Glaxo, Roch,e and in biotech. He has spent the last 25 years specializing in the innovation space with much of that time in seed venture investing focused primarily on university spin-outs.
David was also a senior independent director, audit committee member, and chair of the nominations committee to The Worldwide Healthcare Trust plc, a leading investment trust. He also spent three years establishing and managing the inaugural seed fund at LifeArc. David has degrees from Oxford (English), King’s London (Medicine,) and Harvard.
About Dame Julia King
Dame Julia King, Baroness Brown of Cambridge, joined the Frontier IP Board of Directors in October 2021 as an independent Non-Executive Director and will, with effect from today following the appointments of Nigel and David, assume the role of Senior Independent Director on the board.
About Frontier IP
Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialization services. A critical part of the Group’s work is involving relevant industry partners at an early stage of development to ensure the technology meets real-world demands and needs.
The Group looks to build and grow a portfolio of equity stakes and licensee income by taking an active involvement in spin-out companies, including support for fundraising and collaboration with relevant industry partners at an early stage of development.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.